Crescent Biopharma Gets FDA Clearance For Next-Gen Cancer ADC CR-002

The FDA cleared Crescent Biopharma’s IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor antibody-drug conjugate being developed for advanced solid tumors. The clearance allows the company to advance the investigational drug into clinical development; no trial results or timing were reported.